Antiemetic combination therapy

This page covers all Antiemetic combination therapy drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Glucocorticoid receptor, NK-1 receptor, 5-HT3 receptor.

Targets

Glucocorticoid receptor, NK-1 receptor, 5-HT3 receptor

Phase 3 pipeline (1)

• Dexamethasone+NK-1 RA+5-HT3 RA · Fifth Affiliated Hospital, Sun Yat-Sen University · Oncology (supportive care)
  This triple-agent combination blocks chemotherapy-induced nausea and vomiting (CINV) through corticosteroid anti-inflammatory action, neurokinin-1 receptor antagonism, and serotonin 5-HT3 receptor antagonism.

Patent intelligence

• antiemetic combination therapy patent landscape — aggregated cliff calendar, attackable patents, originator estates